Posted by Michael Wonder on 31 Jul 2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention
30 July 2018 - Aimovig is the first and only approved migraine prevention treatment designed specifically to block the calcitonin gene-related peptide receptor, which plays a critical role in migraine.
Novartis announced today that the European Commission approved Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia.
In the extensive clinical program of 2,600 patients, those on Aimovig experienced significant reductions in their number of migraine days per month, with a safety and tolerability profile similar to placebo. Aimovig can be self-administered or administered by another trained person every four weeks with the SureClick auto-injector pen, an established device commonly used for a range of different conditions.
